Summary

Overview
The global anal fissure therapeutics market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
An anorectal condition marked by inflammation or tearing of the lining of the lower rectum is known as an anal fissure. During bowel movements, it causes considerable discomfort and blood. The ailment is not life-threatening, but it has a major impact on a person's quality of life.
This can help increase blood flow to the fissure and promote healing. It also can help relax the anal sphincter. The majority of chronic anal fissures can be treated effectively by local application of isosorbide dinitrate.
Moreover, the market is driven by factors such as the rising cases of acquired immunodeficiency syndrome, the increasing prevalence of anal fissures, and rising awareness among the people.
Market Dynamics: Drivers
Rising Cases of Acquired Immunodeficiency Syndrome
The demand for the anal fissure therapeutics market is driven by multiple factors. Growing awareness of various treatment choices, advancements in medications and surgical processes like laser therapy, and a reduction in the social stigma associated with its treatment contribute to the market's expansion.
Rising TB cases, cancer, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease. Furthermore, hormonal changes in pregnant women promote constipation, which leads to anal fissures. Anal fissures can also be caused by childbirth stress. Other risk factors include anal sex, ulcerative colitis, and Crohn's disease.
Moreover, Constipation is common among Americans. Constipation affects almost everyone at some point in their lives, with a recent poll revealing that 16% of Americans and one-third of those over 60 suffer from chronic constipation. These factors are likely to boost the anal fissure therapeutics market.
In addition, key players in the industry launched new products that would drive the market growth. For instance, in January 2021, Ipsen reported that in 5 therapeutic indications, a sizable fraction of patients treated with its Dysport (abobotulinumtoxinA) did not necessitate retreatment.
Also, in May 2022, MOVICOL HD, a medication to treat chronic constipation, was introduced in Japan by Eisai Co., Ltd., and Mochida Pharmaceutical Co., Ltd., Adults and children of 2 years of age and older are prescribed to use it.
Restraints
Factors such as product recalls, the harmful adverse effects of medication, the high cost associated with the procedures, and the lack of awareness about anal fissure treatment are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The anal fissure therapeutics market is segmented based on treatment, route of administration, distribution channel, and region.
The calcium channel blockers segment accounted for approximately 49.5% of the anal fissure therapeutics market share
The calcium channel blockers segment is expected to hold the largest market share over the forecast period. Calcium channel blockers are antihypertensive medicines. They function by blocking calcium from entering the heart and artery cells. Calcium causes the heart and arteries to constrict more tightly.
Calcium channel blockers allow blood arteries to relax and open by inhibiting calcium. Infants and middle-aged people are the most commonly affected by anal fissures. Every year, around 235,000 new cases of an anal fissure are reported in the United States.
As per NHS news in November 2024, topical calcium channel blockers work by relaxing the sphincter muscle and increasing blood supply to the fissure. CCBs, such as diltiazem or nifedipine, lower blood pressure and ease anal sphincter spasms. One calcium channel blocker is nifedipine (CCB). It functions in anal fissures by preventing calcium from acting on the anus's blood vessels.
Geographical Analysis
North America accounted for approximately 42.3% of the anal fissure therapeutics market share
North America region is expected to hold the largest market share over the forecast period due to the region's rapid implementation of innovative technologies, a substantial percentage of individuals living with inflammatory bowel diseases, and the major investments made to the healthcare system by the public and private sectors.
According to the Mayo Clinic's 2022 report, more than 1,000 patients receive surgery for anal fistulas each year, demonstrating the doctors' considerable experience in managing these conditions in the United States. Furthermore, it is projected that continuous developments in the field of anal fissure therapy in North America will support market expansion throughout the projected period
Owing to the widespread use of advanced treatment. Another significant market driver is the high rate of blockage among patients. According to the American Gastroenterological Association, about 60% of Americans suffer from this illness. Medicines required for rapid recovery are likely to accelerate the growth of the anal fissure treatment market.
The North American region is developing novel treatment alternatives. Furthermore, rising death rates increased patient awareness about the disease. Advanced healthcare infrastructure is expected to drive the growth of the anal fissure therapeutics market in North America.
Moreover, major player's strategies such as partnerships and collaboration would propel the market growth. AstraZeneca Plc, a pharmaceutical and biotechnology company headquartered in the UK that specializes in the research and marketing of prescription pharmaceuticals, acquired Alexion Pharmaceuticals Inc. in July 2021.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the anal fissure therapeutics market. The pandemic has hampered progress in several countries across multiple disciplines. The COVID-19 outbreak continued to harm important major participants in the anal fissure treatment industry.
However, many producers are struggling due to supply chain delays caused by lockdowns in various nations in the third quarter. However, the negative impact is being partially compensated in several ways, such as utilizing numerous distribution alternatives and online channels.
Market Segmentation
By Treatment
- Nitrate Ointment
- Calcium Channel Blockers
- Botox Injections
- Others
By Route of administration
- Oral
- Topical
- Others
By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the anal fissure therapeutics market include Takeda Pharmaceuticals, Manus Aktteva, Pfizer, AbbVie, Pfizer, Farmacosmo, Silvergate Pharmaceuticals, Covis Pharmaceuticals, Novartis AG, Trumachealthcare, Taj Pharmaceuticals, among others.
Key Developments
- On March 1, 2024, Nitroglycerin ointment is an excellent treatment for anal fissure because many patients prefer to forgo surgery; Glyceryl trinitrate topical treatment has been shown in studies to reduce maximum anal resting pressures in patients with a range of anal pathologies.
- On February 13, 2024, Ossium Health, Inc. to treat refractory perianal fistulas in Crohn's disease patients, submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA).
- On October 18, 2023, Takeda announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data.
- On February 16, 2022, Takeda filed a new drug application in Japan to manufacture and market. Darvadstrocel for the treatment of complex perianal fistulas in adult Crohn's disease patients.
Why Purchase the Report?
- To visualize the anal fissure therapeutics market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of anal fissure therapeutics market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Treatment mapping is available in excel consisting of key treatments of all the major players.
The anal fissure therapeutics market report would provide approximately 65 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Distribution channel
3.3. Snippet by Route of Administration
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Emergence of Novel Treatment
4.1.1.2. Rising Cases of Acquired Immunodeficiency Syndrome
4.1.1.3. Increasing Adoption of Sedentary Lifestyle
4.1.2. Restraints
4.1.2.1. Product Recalls
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Nitrate Ointment *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Portable Anal fissure therapeutics
7.4. Calcium Channel Blockers
7.5. Botox Injections
7.6. Others
8. By Route of administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
8.1.2. Market Attractiveness Index, By Distribution channel
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Others
9. By Distribution channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
9.1.2. Market Attractiveness Index, By Distribution channel
9.2. Hospital Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Takeda Pharmaceuticals *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Manus Aktteva
12.3. Pfizer
12.4. Abbvie
12.5. Farmacosmo
12.6. TransLite LLC
12.7. Silvergate Pharmaceuticals
12.8. Covis Pharmaceuticals
12.9. Novartis AG
12.10. Trumachealthcare
12.11. Taj Pharmaceuticals
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us